search
Pharmaceutical Journal
Trends
- 1WSJ warns U.S. tariffs are hurting American biotech●The U.S. Tariff Attack on U.S. Biotech https://www.wsj.com/opinion/the-u-s-tariff-attack-on-u-s-biotech-c3406b92?mod=rss
The Wall Street Journal's opinion section argues that U.S. tariff policy is damaging the domestic biotechnology industry, which the piece frames as an ironic case of Washington's trade measures attacking American companies. The article is being shared in economic and policy discussions, drawing attention to the tension between protectionist trade policy and the administration's stated goal of strengthening U.S. industrial and pharmaceutical sectors.
- 2WSJ Health Care Market Talk Roundup Published●Health Care Roundup: Market Talk https://www.wsj.com/business/health-care-roundup-market-talk-5f95b714?mod=rss_markets_m
The Wall Street Journal has published its latest Health Care Roundup: Market Talk, a recurring digest of market-moving developments and analyst commentary across the health care sector. It covers the business and finance stories investors in pharmaceutical, biotech and health services stocks are tracking today.
- 3WSJ Health Care Market Talk Roundup Published▼Health Care Roundup: Market Talk https://www.wsj.com/business/health-care-roundup-market-talk-e04aa2dd?mod=rss_markets_m
The Wall Street Journal has published its latest Health Care Roundup as part of its Market Talk series, collecting commentary and market-moving developments from the health care and pharmaceutical sectors. The roundup aggregates analyst remarks on health care stocks, industry trends and regulatory matters for investors tracking the sector's performance.
- 4Pharmacy regulator misses fitness-to-practise timeliness standard for eighth year▼Regulator fails timely fitness-to-practise standard for eighth year running
The General Pharmaceutical Council's regulator has failed to meet the required standard for completing fitness-to-practise cases on time for the eighth consecutive year, according to the Pharmaceutical Journal. The repeated delays mean investigations into pharmacists' conduct are taking longer than the accepted benchmark, raising fresh concerns about the effectiveness of the regulator's disciplinary processes.
- 5
The Pharmaceutical Journal is highlighting the human cost of global medicine shortages, arguing that supply failures are leading to deaths that could have been prevented. The piece frames drug shortages not as an abstract logistics problem but as a direct threat to patient survival, adding to growing international concern over unreliable supplies of essential medicines.